Datapoint: Pfizer, J&J Settle Remicade-Inflectra Legal Battle

Pfizer and Johnson & Johnson have settled their legal battle over anticompetitive practices marketing their two immunology drugs, J&J’s blockbuster Remicade and Pfizer’s biosimilar Inflectra, according to a report from the American Journal of Managed Care’s Center for Biosimilars. While terms of the settlement were not disclosed, Pfizer will continue to market Inflectra. For the treatment of ulcerative colitis, Remicade remains advantaged over Inflectra, holding covered or better status for 59% of all insured lives under the pharmacy benefit and 91% under the medical benefit. Meanwhile, Inflectra is covered or better for 50% of lives under the pharmacy benefit and 90% under the medical benefit.

SOURCE: MMIT Analytics, as of 7/28/21

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 11

Datapoint: Kansas Rejects Medicaid Contract Challenges

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 10

Datapoint: FDA Approves Sandoz, Samsung Bioepis’ Stelara Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 9

Datapoint: FDA Approves Lilly’s New Alzheimer’s Drug

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today